Ramón Cacabelos, a world known expert for neurodegenerative disorders and genomic medicine, and his team have completed preclinical and clinical studies with a nutraceutical called AtreMorine. The exceptional results shows that AtreMorine protects selectively dopaminergic neurons and significantly increases naturally the dopamine level in the organism and without any reverse effects.
Parkinson’s disease, with known symptoms as tremors, stiffness, slowness of movements, depression and other , is mainly due to the progressive degeneration of dopaminergic neurons. These dopaminergic neurons are quite rare in the brain and they die gradually.
An estimated loss of 5 to 10% of these neurons degenerate per decade in everybody’s brain and this process starts more or less at the age of 20. This degeneration occurs even more rapidly in persons affected by Parkinson’s disease and once the loss of these neurons reaches the critical 60-80% barrier, all known symptoms of this disease appear.
To produce dopamine, the body needs its precursor L-dopa. If L-dopa is given to the organism, it will transform it into dopamine. If the body can not produce enough dopamine through its dopaminergic neurons because too many of them died, then we give the synthetic drug L-dopa producing good results for an average of 3 to 10 years. But as we know, unfortunately, despite the very interesting and confirmed results on the symptoms, especially in the early phases, these conventional medical drugs are not able to cure and the destruction of the remaining dopaminergic neurons continues.
Professor Ramon Cacabelos and his team studied and developed during the last seven years this exceptional bioproduct which has significant performances over disorders due to the lack of dopamine which is the case of Parkinson’s disease.
This study was recently published in the “Journal of Genomic Medicine and Pharmacogenomics Scitcentral” with all references to the pre-clinical and clinical results of this nutraceutical whose scientific name is E-PodoFavalin-15999, distributed under the name AtreMorine.
The participants in this clinical study were divided into two groups: on one side the Parkinson patients being already in long term treatment with classical antiparkinsonian drugs and on the other side Parkinson’s patients never being in a medical treatment against Parkinson.
The first remark was that 100% of patients without antiparkinson treatment had dramatic hypodopaminergic levels, with dopamine plasma below 20 pg / mL. This is far to less for the body and this make it evident that it is important to take medical treatments in the case of Parkinson’s disease.
Respecting the other scientific results of this study, they were numerous, very promising and encouraging in both groups of patients giving significant solutions for Parkinson’s patients:
The scientific study reveals, that the first beneficial effect of AtreMorine is the selective protection of dopaminergic neurons, that means:
“so far, no remedy allowed to stop or decrease significantly the loss of dopaminergic neurons, but thanks to AtreMorine that is possible now.”
The second most important beneficial effect of AtreMorine for Parkinson patients, revealed in the study, is its ability to increase significantly levels of dopamine in the body thanks to the enormously rich content of natural L-DOPA (average concentration: 20mg/g).
The scientific study indeed showed that:
“A single dose of 5-10 grams of AtreMorine increases dopamine levels in average range by 500% – 4000% in 30 minutes, and it’s effects remain up to 12 hours, improving in parallel the cardinal symptoms of Parkinson’s disease: tremor, bradykinesia and rigidity.”
The nutraceutical is made out of 100% natural plant extracts with a patented extraction method that protects the active principals. Another important factor the study showed, was the fact that the nutraceutical was tolerated by 100% of patients without any adverse effects.
AtreMorine has also shown other beneficial effects with a powerful regulation the noradrenaline and the hormones of the pituitary gland, such as prolactin and growth hormone which takes part in the control of supra-hypothalamic dopaminergic neurotransmission as mentioned in the study.
The noradrenaline as as well as the dopamine are very important in regulation of the mood of the persons. Many studies show that sadness and depression are regular phenomenon observed in almost 30% of patients with parkinson.
The study suggests that AtreMorine can contribute to:
- Reduce the phenomenon “wearing off” or “end-of-dose deterioration” (observed essentially in the intermediate and advanced phases).
- Help to improve the therapeutic effect of conventional antiParkinson drugs and delay the loss of long term response (from the initial to the advanced phase).
- Reduce at the same time the short term and long term adverse effects and long duration (from the initial to the advanced phase).
The study reveals precisely that co-administration of nutraceutical AtreMorine with antiparkinsonian drugs, allows a reduction of the conventional medicine dose between 25 to 50%, with clinical benefits and significant reduction of short and long term adverse of these drugs. Consequently, patients could use antiparkinsonian drugs over a much longer period.
This is how this nutraceutical showed its utility in all stages of Parkinson’s disease (initial, intermediate and advanced stages). It could also be an option particularly for patients with serious adverse reactions and who can not take antiparkinson drugs or those having greater tolerance to natural products.
The promising results of this study suggests that AtreMorine contribute to significantly improve the lives of thousands of persons and their families nowadays. In addition to this, Atremorine could not not only help persons already suffering with parkinson’s disease and who need urgent help right now, but also help to prevent degeneration by persons exposed to a high level of pesticides for example, or those with medical family records for Parkinson’s disease.
Atremorine is situated first of all as a complement to the anti-parkinsonian drugs with their beneficial effects over the symptoms.